Australia to reimburse Alexion's Soliris, Celgene's Vidaza and GSK's Avodart
This article was originally published in Scrip
Executive Summary
Australia is to reimburse Alexion Pharmaceuticals' expensive orphan blood therapy Soliris (eculizumab), Celgene's bone marrow drug Vidaza (azacitidine) and GlaxoSmithKline's benign prostate enlargement treatment Avodart (dutasteride) from early next year.